GLAMOR-M [Glimepiride 2 mg + Metformin Hydrochloride IP 500 mg (ER)]: Uses, MOA, Benefits, and Recommended Dosage

  • Post category:Blog
  • Post comments:0 Comments
  • Reading time:7 mins read
GLAMOR-M Glimepiride 2 mg Metformin Hydrochloride IP 500 mg


GLAMOR-M stands as a beacon of hope for individuals grappling with type 2 diabetes. This comprehensive guide elucidates the combined benefits of Glimepiride and Metformin Hydrochloride IP 500 mg (ER) encapsulated in GLAMOR-M tablets. Explore how this innovative formulation from Invision Medi Sciences plays a pivotal role in optimizing diabetes management.

Harnessing the Power of Glimepiride and Metformin:

GLAMOR-M combines the glucose-lowering effects of Glimepiride and Metformin Hydrochloride, offering a synergistic approach to diabetes management. Dive into the mechanisms of action and therapeutic advantages conferred by these two potent agents.

Indications for GLAMOR-M:

  1. Type 2 Diabetes Mellitus: GLAMOR-M is indicated for the treatment of type 2 diabetes mellitus to achieve glycemic control.
  2. Combination Therapy: It serves as an adjunct to diet and exercise in individuals inadequately controlled on monotherapy or those requiring dual therapy.

Benefits of GLAMOR-M:

  1. Blood Glucose Regulation: Glimepiride stimulates insulin secretion, while Metformin improves insulin sensitivity and reduces hepatic glucose production, collectively aiding in blood glucose regulation.
  2. Weight Management: Metformin’s potential for weight neutrality or modest weight loss complements Glimepiride’s glucose-lowering effects, offering a comprehensive approach to diabetes management.

Recommended Dosage:

The dosage of GLAMOR-M should be individualized based on the patient’s glycemic response and tolerability. Healthcare providers typically initiate therapy with one tablet once or twice daily, gradually titrating the dose to achieve optimal glycemic control.

Potential Side Effects:

While generally well-tolerated, GLAMOR-M may cause side effects in some individuals, including:

  • Hypoglycemia: Glimepiride’s insulin secretagogue effect may lead to hypoglycemia, especially in susceptible individuals.
  • Gastrointestinal Disturbances: Metformin may cause gastrointestinal symptoms such as nausea, vomiting, or diarrhea.

Essential Information:

  1. Monitoring Parameters: Regular monitoring of blood glucose levels and renal function is recommended during GLAMOR-M therapy.
  2. Patient Education: Patients should be educated about the signs of hypoglycemia and advised on appropriate self-management strategies.


GLAMOR-M represents a milestone in diabetes management, combining the synergistic effects of Glimepiride and Metformin to achieve optimal glycemic control. With its dual mechanism of action and favorable safety profile, GLAMOR-M exemplifies Invision Medi Sciences’ commitment to empowering individuals in their journey towards better health.

Related Combinations:

Explore our range of diabetes management solutions at Invision Medi Sciences.

GLAMOR-M: Empowering individuals with a dual-action approach to diabetes management.


How does GLAMOR-M help in managing type 2 diabetes?

GLAMOR-M combines Glimepiride and Metformin Hydrochloride to regulate blood glucose levels through insulin secretion and improved insulin sensitivity, respectively.

What is the recommended dosage regimen for GLAMOR-M?

Healthcare providers typically initiate GLAMOR-M therapy with one tablet once or twice daily, adjusting the dose based on individual glycemic response and tolerability.

Can GLAMOR-M cause hypoglycemia?

Yes, GLAMOR-M may lead to hypoglycemia, particularly if the dose is not adjusted appropriately. Patients should be vigilant for signs of low blood sugar levels.

Are there any dietary restrictions while taking GLAMOR-M?

While specific dietary restrictions may not be necessary, maintaining a balanced diet is essential for overall diabetes management and health.

Is GLAMOR-M suitable for individuals inadequately controlled on monotherapy?

Yes, GLAMOR-M serves as an adjunct to diet and exercise in individuals inadequately controlled on monotherapy or those requiring dual therapy for type 2 diabetes.

Leave a Reply

The reCAPTCHA verification period has expired. Please reload the page.